Google Trends: Moderna dominates as the leading COVID-19 vaccine; Tesla and Apple trend high following stock splits.
While the COVID-19 pandemic rises into the fall season, the question of the leading vaccine is shown to be Moderna.
There are roughly nine other vaccine companies racing to finish their trials, Moderna shows to be the most searched vaccine. Pfizer and AstraZeneca are two widely discussed front-runners for the COVID-19 vaccine.
Their supply is expected to be available in Fall 2020.
The next two promising vaccines are Pfizer and AstraZeneca. Pfizer, partnered with BioNTech, and AstraZeneca, are also in Phase 3.
Pfizer explains that its use of mRNA technology attributes to its speed in constructing a vaccine. The company claims to have its vaccine available by October.
AstraZeneca rose in promise once picked up by the University of Oxford.
Australia will be the first to receive their vaccine in January-February of 2021, once their trials are proven successful.
In terms of trends, Moderna follows every spike for the search “vaccine”. The company has a higher search average than its other two competitors shown on this graph, its popularity amongst all, has yet to be determined on Google Trends.
Tesla and Apple Trends following their stock splits
The benefits of a stock split adjustment are attracting more investors to buy the stock at a lower price. Additionally, those that already own stock in either company, prior to the split, will also own more shares.
Apple dominates the stock market as one of the 30 stocks in the S&P Dow Jones.
The company did well during the pandemic quarantining with online sales. Apple’s Mac and iPad sales were a large contribution to their success this quarter.
However, both companies show trending success following their stock split as shown in the spike on August 31, 2020.
Apple generally has a stock spike around September depending on the success of its annual iPhone launches. However, the COVID-19 pandemic delayed its release by a couple of weeks. This may impact its market success in September.